Identification of an EMT-related Gene Signature Predicting Recurrence in Stage II/III Colorectal Cancer
- 26 July 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 276 (5) , 897-904
Abstract
Objective: To identify a prognostic significant gene signature for predicting colorectal cancer (CRC) recurrence. Background: Traditional prognostic risk assessment in stage II/III CRC patients remains controversial. Epithelial-mesenchymal transition is thought to be closely related to the malignant progression of tumors. Thus, it is promising to establish a prognostic model based on epithelial-mesenchymal transition–related gene (ERG) signature. Materials and Methods: We retrospectively analyzed transcriptome profiles and clinical information of 1780 stage II/III CRC patients from 15 public datasets. Coefficient variant analysis was used to select reference genes for normalizing gene expression levels. Univariate, LASSO, and multivariate Cox regression analyses were combined to develop the ERG signature predicting disease-free survival (DFS). The patients were divided into high-risk and low-risk based on the ERG signature recurrence risk score. The survival analysis was performed in different CRC cohorts. Results: The proposed ERG signature contained 7 cancer-related ERGs and 3 reference genes. The ERG signature recurrence risk score was prognostically relevant in all cohorts (PPP=0.0058) than low-risk patients. The predictive performance of the ERG signature was superior to Oncotype DX colon cancer. An integrated decision tree and nomogram were developed to improve prognosis evaluation. Conclusions: The identified ERG signature is a promising and powerful biomarker predicting recurrence in CRC patients. Moreover, the presented ERG signature might help to stratify patients according to their tumor biology and contribute to personalized treatment.Keywords
This publication has 28 references indexed in Scilit:
- Oncotype DX® colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: A review of the evidenceSurgical Oncology, 2015
- Survival Paradox Between Stage IIB/C (T4N0) and Stage IIIA (T1-2N1) Colon CancerAnnals of Surgical Oncology, 2014
- Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinomaTumor Biology, 2014
- ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosisGut, 2012
- Visinin‐like protein‐1 overexpression is an indicator of lymph node metastasis and poor prognosis in colorectal cancer patientsInternational Journal of Cancer, 2011
- Ubiquitin D is correlated with colon cancer progression and predicts recurrence for stage II-III disease after curative surgeryBritish Journal of Cancer, 2010
- Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data SetJournal of Clinical Oncology, 2008
- Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized TrialsJournal of Clinical Oncology, 2005
- Clinical Significance of Human Kallikrein Gene 6 Messenger RNA Expression in Colorectal CancerClinical Cancer Research, 2005
- The epithelial-mesenchymal tansition (EMT) and colorectal cancer progressionCancer Biology & Therapy, 2005